The remarkable scientific progress in the last two decades has given rise to the development of new technologies at an unprecedented pace. ProBioGen is engaged in multiple collaborations. 

Only a few of them are mentioned here:

Life Technologies Corporation 

Together with Life Technologies Corporation (LTC) we engineered the FreedomTM CHO-STM Kit platform which enables cost-and-time-efficient stable cell line development for research and commercial purposes. The kit is available via Life Technologies.

Boehringer Ingelheim/GlymaxX®

Boehringer Ingelheim has taken a non-exclusive license for ProBioGen’s proprietary GlymaxX® ADCC enhancement technology (Antibody-Dependent Cell-Mediated Cytotoxicity). Under this license Boehringer Ingelheim does apply GlymaxX® for third parties from its global Contract Manufacturing Platform as well as to its own development candidates, to produce antibodies with enhanced ADCC potency.


Please contact us at cmo@probiogen.de for references.